Our growing development pipeline of innovative new therapies is driven by the flexibility of our TransCon® technologies and our aim to improve patients' lives. We have multiple prodrug therapies in development. Each candidate is unique and designed to be a best-in-class therapy.
U.S. & Europe4
1Japanese riGHt Trial
2 Global foresiGHt Trial
3New InsiGHTS Trial
4NDA submitted to the FDA; PDUFA action date April 30, 2023, EU MAA submitted November 2022, decision anticipated Q4 2023
5Japanese PaTHway Japan Trial
6Global ApproaCH Trial
7transcendIT-101 Trial. Includes four indication-specific cohorts currently enrolling patients.